Previous 10 | Next 10 |
Recent Data Presentation Highlights Consistent Complete Response Rate and Strong Durability at Six-Months in Evaluable Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Completion of UGN-101 Rolling NDA Submission to the FDA On Track for 2H 2019 Pre-Commercial Activi...
Following up on its initial announcement of topline results in January, UroGen Pharma ( URGN +3.4% ) reports findings from a secondary analysis from the Phase 3 OLYMPUS study of UGN-101 (mitomycin gel) for the non-surgical treatment of low-grade upper tract urothelial cancer ((LGUTUC...
Complete Response (CR) Rate Consistent at 59 Percent Six-month Durability Strong with 89 Percent of Evaluable Patients Remaining in CR Full Phase 3 Data Anticipated for 2H 2019 UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatment...
Conference Call and Webcast Scheduled for 8:30 AM ET UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the market. The announcement will be followed by a live audio webcast and confe...
Noteworthy events during the latter part of the week of April 28 - May 4 for healthcare investors. More news on: UroGen Pharma Ltd., ESSA Pharma Inc., EyePoint Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
Focused Agreement is on Therapeutic Area of Mutual Interest UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an agreement with Janssen Resear...
UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced a new presentation from the pivotal Phase 3 OLYMPUS trial of UGN-101 (mitomycin gel) for instillation, an investigational formulati...
The following slide deck was published by UroGen Pharma Ltd. in conjunction with this Read more ...
UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March: Cowen and Company 39 th Annual Health Care Conference Tuesday, March 12 th 11:20AM Eastern Time Boston, MA Oppenheimer 29 th Annual Hea...
UroGen Pharma (URGN) Q4 2018 Earnings Conference Call February 28, 2019 8:30 A.M. ET Company Participants Kate Bechtold - Director, Corporate Communications and Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer Peter ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...